Aminoglycoside Derivatives for Stop Codon Readthrough
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current aminoglycosides used to treat genetic disorders are limited by high toxicity, antimicrobial activity, low bioavailability, and poor permeability into eukaryotic cells, making them ineffective for treating genetic diseases with premature stop codon mutations.
Innovation Solution
Development of novel aminoglycoside derivatives with modified paromomycin structures that exhibit high read-through activity for premature stop codon mutations, low toxicity in mammalian cells, and improved bioavailability and cell permeability, characterized by specific structural modifications such as hydroxyl groups, monosaccharide moieties, and amino-substituted alpha-hydroxy acyl groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional aminoglycosides are used to treat premature stop codon mutations, then read-through activity is achieved, but high toxicity and antimicrobial activity occur
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of aminoglycosides through various substitutions at specific positions (1, 2, 3, 4, 6, and other positions of the paromomycin core). These structural parameter changes include replacing hydroxyl groups with different moieties, adding or removing sugar residues, and introducing various functional groups to achieve the desired balance between read-through activity and reduced toxicity/antimicrobial activity.
Solution Approach 2:
The patent creates composite chemical structures by combining the paromomycin core with various additional moieties and substituents. The modified aminoglycosides consist of multiple components including the core structure, sugar residues, and various functional groups that work together to provide both therapeutic read-through activity and reduced harmful effects.
2Reliability
If conventional aminoglycosides are used for stop codon suppression, then some read-through effect is achieved, but low bioavailability and poor cell permeability limit effectiveness
Solution Approach 1:
The patent improves bioavailability and cell permeability through parameter changes in the molecular structure. Specific modifications include adding lipophilic groups, adjusting the overall charge distribution, and modifying the size and shape of the molecule to enhance membrane penetration while maintaining the essential read-through activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These derivatives effectively increase protein expression in cells with premature stop codon mutations, reducing toxicity and antimicrobial activity, thereby providing a more effective treatment for genetic disorders like cystic fibrosis and Rett syndrome.
Implementation Method 1
The enhancement of termination suppression by aminoglycosides in eukaryotes is thought to occur in a similar mechanism to the aminoglycosides' activity in prokaryotes of interfering with translational fidelity during protein synthesis, namely the binding of certain aminoglycosides to the ribosomal A-site probably induce conformational changes that stabilize near-cognate mRNA-tRNA complexes
Data Source
AI summary
Novel aminoglycosides, represented by Formulae Ia and Ib, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.